Merck & Co. led the antibody-drug conjugate (ADC) shopping spree last year with its multi-billion dollar deal with Daiichi Sankyo, but now the U.S. pharma clearly wants to further fine-tune its ADC ...
NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results